Status:
COMPLETED
Study Examing The Effect of Grapefruit Juice On The Blood And Urine Samples of Study Drug And Its By Product And Safety
Lead Sponsor:
Pfizer
Conditions:
Obesity
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
CP-945,598 is eliminated primarily by enzyme CYP3A. Grapefruit juice may affect the activity of CYP3A and alter the amount of CP-945,598 in the blood. This study will therefore compare the time course...
Eligibility Criteria
Inclusion
- Healthy male and female subjects between the ages of 18 and 55 years.
- Body Mass Index (BMI) of 27 to 40 kg/m2.
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.
Exclusion
- Non-prescribed use of drugs of abuse/ recreational drugs;
- Recent treatment with experimental drugs or herbal experiments;
- EKG and blood pressure parameters falling outside of protocol-specified limits;
- History of regular alcohol or tobacco use exceeding protocol-specified limits; grapefruit juice intolerance.
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2007
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00645216
Start Date
June 1 2007
End Date
October 1 2007
Last Update
August 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511